Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026
Antithrombotic agents: Do they protect from infective endocarditis? A retrospective observational study using TriNetx.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gotor-Rivera Alfonso, Alejo Fernández-Baillo José Luis, Acosta-Hernández Julián, Carpy María Del Pilar, Infanta Marta Del Río de la, López-Medrano Francisco
Аннотация
INTRODUCTION: Infective endocarditis (IE) remains a severe infection associated with substantial morbidity and mortality. Given the central role of platelets in its pathogenesis, antithrombotic therapy has been hypothesized to exert a preventive effect, though clinical evidence remains inconclusive.
METHODS: We conducted a retrospective, population-based study using the TriNetX Global Collaborative Network to assess the incidence of IE among individuals exposed to antiplatelet or anticoagulant therapy versus untreated controls. Propensity score matching accounted for major cardiovascular and metabolic comorbidities, and outcomes were evaluated over a 10-year follow-up period.
RESULTS: In low-risk individuals, neither antiplatelet nor anticoagulant use significantly reduced IE incidence. In high-risk patients, only anticoagulant (HR 0.55, 95%CI 0.29-1.07) therapies non-significantly reduced IE risk.
CONCLUSION: Antithrombotic therapy has not demonstrated protective effects against infective endocarditis. These findings warrant prospective studies to elucidate mechanisms and confirm safety.
METHODS: We conducted a retrospective, population-based study using the TriNetX Global Collaborative Network to assess the incidence of IE among individuals exposed to antiplatelet or anticoagulant therapy versus untreated controls. Propensity score matching accounted for major cardiovascular and metabolic comorbidities, and outcomes were evaluated over a 10-year follow-up period.
RESULTS: In low-risk individuals, neither antiplatelet nor anticoagulant use significantly reduced IE incidence. In high-risk patients, only anticoagulant (HR 0.55, 95%CI 0.29-1.07) therapies non-significantly reduced IE risk.
CONCLUSION: Antithrombotic therapy has not demonstrated protective effects against infective endocarditis. These findings warrant prospective studies to elucidate mechanisms and confirm safety.